<SEC-DOCUMENT>0001193125-20-086927.txt : 20200326
<SEC-HEADER>0001193125-20-086927.hdr.sgml : 20200326
<ACCEPTANCE-DATETIME>20200326160656
ACCESSION NUMBER:		0001193125-20-086927
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200323
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200326
DATE AS OF CHANGE:		20200326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			89bio, Inc.
		CENTRAL INDEX KEY:			0001785173
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831114349
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39122
		FILM NUMBER:		20746204

	BUSINESS ADDRESS:	
		STREET 1:		535 MISSION STREET
		STREET 2:		14TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94105
		BUSINESS PHONE:		4155004614

	MAIL ADDRESS:	
		STREET 1:		535 MISSION STREET
		STREET 2:		14TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94105
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d140983d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif; width:8.5in; margin:auto"> <P STYLE="margin: 0">&nbsp;</P> <P STYLE="margin: 0"></P>
<DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 0.75pt solid">&nbsp;</DIV></DIV>
 <P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>UNITED STATES </B></P> <P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND
EXCHANGE COMMISSION </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV>
 <P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B>FORM 8-K </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV>
 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B>CURRENT REPORT </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to
Section&nbsp;13 or 15(d) </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B>Date of Report (Date of earliest event reported): March&nbsp;23, 2020 </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV>
 <P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B>89bio, Inc. </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of
registrant as specified in its charter) </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV>
 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="width: 34%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="width: 32%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
<TD STYLE="width: 32%">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
<TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-39122</B></FONT></TD>
<TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>36-4946844</B></FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(State or other jurisdiction</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center"><B>of incorporation)</B></P></TD>
<TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="vertical-align: top"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Commission</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center"><B>File
Number)</B></P></TD>
<TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="vertical-align: top"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(IRS Employer</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center"><B>Identification
No.)</B></P></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B>142 Sansome Street, Second Floor </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>San Francisco, CA 94104 </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices,
including zip code) </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B>(415) 500-4614 </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Registrant&#8217;s telephone number, including area code) </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Not Applicable</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Former name or former address, if changed since last report) </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV>
 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR> </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR> </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR> </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) </FONT></TD></TR> </TABLE>
 <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR>
<TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV> <DIV STYLE="page-break-before: always; margin-top: 6pt">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR>
<TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0">Securities registered pursuant to Section&nbsp;12(b) of the Act:</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="width: 34%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="width: 32%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
<TD STYLE="width: 32%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Trading</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center"><B>Symbol(s)</B></P></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Name of each exchange</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center"><B>on which registered</B></P></TD></TR>
<TR>
<TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Stock, par value $0.001 per share</B></FONT></TD>
<TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>ETNB</B></FONT></TD>
<TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>The Nasdaq Global Market</B></FONT></TD></TR> </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or
Rule&nbsp;12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: right">Emerging growth company&nbsp;&nbsp;<FONT
STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 0.75pt solid">&nbsp;</DIV></DIV>

 <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR>
<TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV> <DIV STYLE="page-break-before: always; margin-top: 6pt">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR>
<TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Item&nbsp;5.02</B></FONT></TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.</B></FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><I>Director Appointment</I></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">On March 23, 2020, the board of
directors (the &#8220;Board&#8221;) of 89bio, Inc. (the &#8220;Company&#8221;) appointed Steven M. Altschuler, M.D. to the Board as Chairman. Dr. Altschuler will serve as a Class II Director until the Company&#8217;s 2021 Annual Meeting of
Stockholders and until his successor is duly elected and qualified, effective immediately.</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Dr. Altschuler, age 66, has served as a Managing Director, Healthcare Ventures, of
Ziff Capital Partners, a private investment firm, since May 2018. He previously served as a consultant to the University of Miami Health Care System from September 2017 through December 2017, the Chief Executive Officer of University of Miami Health
Care System and Executive Vice President for Healthcare at the University of Miami from January 2016 to September 2017, and the Chief Executive Officer of The Children's Hospital of Philadelphia (CHOP) from April 2000 until June 2015. Prior to
assuming the role of Chief Executive Officer, Dr. Altschuler held several positions at CHOP and the Perelman School of Medicine at the University of Pennsylvania, including Physician-in-Chief / Chair of Pediatrics and chief of the Division of
Gastroenterology, Hepatology and Nutrition. Dr. Altschuler has served as a director of WW International, Inc. since September 2012, as a director of Adtalem Global Education Inc. since May 2018 and as a director of Orchard Therapeutics plc since
January 2020. He previously served as Chair of the board of directors of Spark Therapeutics, Inc. from March 2013 to December 2019. Dr. Altschuler received a B.A. in mathematics and an M.D. from Case Western Reserve University.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">In accordance with the Company&#8217;s non-employee director compensation policy, which is described in the Company&#8217;s Annual Report on Form 10-K for the year ended December
31, 2019, Dr. Altschuler will receive an annual cash retainer of $70,000 for his service as Chairman. In addition, Dr. Altschuler was granted an option to purchase 40,000 shares of the Company&#8217;s common stock at an exercise price equal to the
average closing price of the Company&#8217;s common stock on The Nasdaq Global Market over the ten trading day period ending on the date of grant. The equity awards were made under the Company&#8217;s Amended and Restated 2019 Equity Incentive Plan.
The shares underlying the option will vest and become exercisable on the first, second and third anniversary of the date of grant, subject to Dr. Altschuler&#8217;s continued service to the Company. Dr. Altschuler will enter into the Company&#8217;s
standard form of indemnification agreement, which was previously filed by the Company as Exhibit 10.1 to the Company&#8217;s Form S-1 filed on October 11, 2019.</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">There are no
arrangements or understandings between Dr. Altschuler and any other persons pursuant to which he was elected as a director of the Company. There are no family relationships between Dr. Altschuler and any director or executive officer of the Company,
and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">On March&nbsp;25, 2020, the Company
issued a press release announcing Dr. Altschuler&#8217;s appointment. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><I>2019
Director Compensation</I></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">On March 18, 2020, the Company filed its Annual Report on Form 10-K for the year ended December 31, 2019 (the &#8220;Form 10-K&#8221;) which
contained certain disclosures regarding the compensation of the Company&#8217;s non-employee directors. At the time of such filing, the Company had not yet determined fees payable to the non-employee directors for their service on the board of
directors from the completion of its initial public offering through the end of the fiscal year ended December 31, 2019. The Company has now determined such payments. In accordance with applicable rules of the Securities and Exchange Commission
(&#8220;SEC&#8221;), this Form 8-K is being filed to update certain disclosures previously included in the Form 10-K to reflect the actual amounts paid or to be paid to non-employee directors for 2019.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>Director Compensation</B></P>
 <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR>
<TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV> <DIV STYLE="page-break-before: always; margin-top: 6pt">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR>
<TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 32.05pt">The following table sets forth the total cash and equity compensation paid to our&nbsp;non-employee&nbsp;directors for service on our
board of directors during 2019:</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
<TD STYLE="border-bottom: black 1pt solid; padding-top: 0.75pt; padding-right: 0.75pt"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
<TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-top: 0.75pt; padding-right: 0.75pt"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fees&nbsp;Earned&nbsp;or</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Paid&nbsp;in&nbsp;Cash&nbsp;($)<SUP>(1)</SUP></B></P></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-top: 0.75pt; padding-right: 0.75pt"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Option&nbsp;Awards</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>($)<SUP>(2)</SUP></B></P></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-top: 0.75pt; padding-right: 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total&nbsp;($)</B></FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD></TR>
<TR STYLE="background-color: #CFF0FC">
<TD STYLE="vertical-align: top; width: 46%; padding-top: 0.75pt; padding-right: 0.75pt"><FONT STYLE="font-size: 10pt">Michael Hayden</FONT></TD>
<TD STYLE="vertical-align: bottom; width: 1%; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; width: 1%; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; width: 17%; border-top: black 1pt solid; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">40,006</FONT></TD>
<TD STYLE="white-space: nowrap; width: 1%; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; width: 1%; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; width: 1%; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; width: 14%; border-top: black 1pt solid; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">82,764</FONT></TD>
<TD STYLE="white-space: nowrap; width: 1%; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; width: 1%; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; width: 1%; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; width: 14%; border-top: black 1pt solid; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">122,770</FONT></TD>
<TD STYLE="white-space: nowrap; width: 1%; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
<TD STYLE="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt"><FONT STYLE="font-size: 10pt">Derek DiRocco</FONT></TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">6,667</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8212;</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">6,667</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD></TR>
<TR STYLE="background-color: #CFF0FC">
<TD STYLE="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt"><FONT STYLE="font-size: 10pt">Gregory Grunberg</FONT></TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">8,334</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8212;</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">8,334</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
<TD STYLE="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt"><FONT STYLE="font-size: 10pt">Tomer Kariv</FONT></TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">4,167</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8212;</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">4,167</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD></TR>
<TR STYLE="background-color: #CFF0FC">
<TD STYLE="vertical-align: top; padding-top: 0.75pt; padding-right: 0.75pt"><FONT STYLE="font-size: 10pt">Anat Naschitz</FONT></TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">8,334</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8212;</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt; text-align: right"><FONT STYLE="font-size: 10pt">8,334</FONT></TD>
<TD STYLE="white-space: nowrap; padding-top: 0.75pt; padding-right: 0.75pt">&nbsp;</TD></TR> </TABLE>
<DIV STYLE="margin: 1pt 622.75pt 1pt 0in; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 0.75pt solid">&nbsp;</DIV></DIV>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="white-space: nowrap; padding-top: 2pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
<TD COLSPAN="2" STYLE="padding-top: 2pt"><FONT STYLE="font-size: 10pt">Dr.&nbsp;Hayden is party to a letter agreement with the Company pursuant to which the Company pays him a monthly fee of $3,333 for service on the Board. </FONT></TD></TR>
<TR>
<TD STYLE="white-space: nowrap; vertical-align: top; width: 8%"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
<TD STYLE="vertical-align: top; width: 91%"><FONT STYLE="font-size: 10pt">Amounts shown in this column represent the aggregate grant date fair value (calculated in accordance with FASB Accounting Standards Codification Topic 718) of stock options
granted during the year. A description of the methodologies and assumptions we use to value equity awards and the manner in which we recognize the related expense are described in Note 9 to our consolidated financial statements included in our
Annual Report on Form 10-K, Share-Based Compensation, filed with the SEC on March 18, 2020. These amounts may not correspond to the actual value eventually realized by the director because the value depends on the market value of our common stock at
the time the award is exercised. As of December&nbsp;31, 2019, Dr.&nbsp;Hayden held 134,214 outstanding stock options, of which 36,692 were exercisable. No other non-employee director held any outstanding equity awards as of such date.</FONT></TD>
<TD STYLE="width: 1%">&nbsp;</TD></TR> </TABLE> <P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 9%"><FONT STYLE="font-size: 10pt"><B>Item&nbsp;9.01</B></FONT></TD>
<TD><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits </B></FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0">(d)<I>&nbsp;Exhibits</I>. The following exhibit is being furnished
herewith:</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 24pt 0 0; text-align: center"><B><U>EXHIBIT&nbsp;INDEX </U></B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
<TD STYLE="width: 93%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="white-space: nowrap"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 1pt solid"><B>No.</B></P></TD>
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
<TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><a href="d140983dex991.htm">Press Release, dated March&nbsp;25, 2020 </A></FONT></TD></TR> </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
 <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR>
<TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV> <DIV STYLE="page-break-before: always; margin-top: 6pt">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR>
<TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="width: 45%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
<TD STYLE="width: 4%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
<TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>89bio, Inc.</B></FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Date: March&nbsp;26, 2020</FONT></TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: top"> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid">/s/ Rohan Palekar</P></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Rohan Palekar</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR> </TABLE> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P> <P STYLE="margin: 0">&nbsp;</P> <P STYLE="margin: 0"></P>
 <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR>
<TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
 <P STYLE="margin: 0">&nbsp;</P> </BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d140983dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
  <BODY> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"></P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt"></P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt">
<IMG SRC="g140983image_001a.jpg" ALT="" STYLE="height: 48px; width: 129px"></P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-right: 0; margin-left: 0"><B><A NAME="a_hlk16585068"></A>89bio Appoints Healthcare Industry
Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors</B></P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify">SAN FRANCISCO, March 25, 2020 -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage
biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Steven Altschuler, M.D., as chairman of its board of
directors. Dr. Altschuler currently serves as managing director of Healthcare Ventures at Ziff Capital Partners. He brings 20 years of experience growing healthcare organizations in business and leadership capacities.</P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify">&ldquo;We are very pleased to welcome Steven as chairman of 89bio&rsquo;s board of directors,&rdquo; said Greg Grunberg, chair of the nominating and corporate
governance committee of 89bio&rsquo;s board of directors. &ldquo;By any measure, Steven has distinguished himself throughout his career as an innovator and dynamic leader in the provider and biotechnology industries. We are incredibly fortunate to
have him join the team and confident he is going to be a significant contributor to 89bio.&rdquo;</P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify">In his role at Ziff Capital Partners, Dr. Altschuler
co-leads the firm&rsquo;s efforts toward investing in, and facilitating the start-up and development of, companies with potentially transformative technologies that emphasize cellular and molecular approaches to human disease. He previously
co-founded Spark Therapeutics to develop and commercialize the preclinical and clinical gene therapy programs advanced at the Children&rsquo;s Hospital of Philadelphia (CHOP) and other institutions. Dr. Altschuler served as Spark Therapeutics&rsquo;
board chair from its founding through its acquisition in 2019, which included leading the company through a successful transition to a public company and the launch of the first gene therapy for an inherited disease approved by the U.S. Food and
Drug Administration and European Medicines Agency.</P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 8pt; text-align: justify">&ldquo;I joined the board of directors because of my enthusiasm for 89bio&rsquo;s potentially
differentiated fibroblast growth factor 21 (FGF21), BIO89-100, and its commercial potential in non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG),&rdquo; said Dr. Altschuler. &ldquo;I look forward to working closely with the
team and the rest of the board to advance our work in liver and cardio-metabolic diseases.&rdquo;</P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify">Trained as a pediatric gastroenterologist, Dr. Altschuler
formerly held CEO positions at CHOP, which is one of the nation&rsquo;s leading children&rsquo;s hospitals, and the University of Miami Health System. He is a member of the board of directors of WW (formerly Weight Watchers International), Orchard
Therapeutics, AsclepiX Therapeutics, ImVaX and Platelet Biogenesis. He is also an independent trustee of the Brigham and Women&rsquo;s Physician Organization at Mass General Brigham. Dr. Altschuler holds a B.A. in mathematics and an M.D. from Case
Western Reserve University.</P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify"><A NAME="a_hlk35413333"></A>&ldquo;Steven is an accomplished business leader who has led and served on the boards of numerous
biotechnology companies,&rdquo; said Rohan Palekar, CEO of 89bio. &ldquo;We look forward to drawing upon his strategic, operational and clinical expertise as we continue to grow the organization and work towards developing differentiated medicines
for patients with liver and cardio-metabolic diseases.&rdquo;</P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify"><B>&nbsp;</B></P>
 <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 33%">&nbsp;</TD>
<TD STYLE="width: 34%; text-align: center; font-family: Times New Roman, Times, Serif">
&nbsp;
</TD>
<TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV> <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
 <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><B>About 89bio</B></P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">89bio is a clinical-stage
biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company&rsquo;s lead product candidate, BIO89-100, is being developed for the treatment
of NASH. The company also intends to develop BIO89-100 for the treatment of SHTG. BIO89-100 is a specifically engineered glycoPEGylated analog of FGF21 that is currently in a proof of concept Phase 1b/2a clinical trial in patients with NASH or NAFLD
and a high risk of NASH. <A NAME="a_hlk526943743"></A>89bio is headquartered in San Francisco with operations in Herzliya, Israel. Visit 89bio.com for more information.</P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify"><B>&nbsp;</B></P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><B>Forward-Looking Statements </B></P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">Certain statements in this press release may constitute &quot;forward-looking statements&quot; within the meaning of the federal securities laws, including, but not
limited to, 89bio&rsquo;s expectations regarding plans for its clinical programs and clinical studies. Words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;objective,&rdquo; &ldquo;intend,&rdquo; &ldquo;should,&rdquo;
&ldquo;could,&rdquo; &ldquo;can,&rdquo; &ldquo;would,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;design,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo; &ldquo;develop,&rdquo; &ldquo;plan&rdquo; or the
negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While 89bio believes these forward-looking statements are reasonable, undue reliance should not be
placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and
uncertainties (including, without limitation, those set forth in 89bio&rsquo;s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond 89bio&rsquo;s control and subject to change. Actual results could be materially
different. 89bio expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.</P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt; text-align: justify">###</P>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt">Investor Contact:<BR> Ryan Martins<BR> Chief Financial Officer<BR> investors@89bio.com</P> <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt">Media Contact:<BR>
Lori Rosen<BR> LDR Communications<BR> 917-553-6808<BR> lori@ldrcommunications.com<BR> <BR> </P>
 <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 33%">&nbsp;</TD>
<TD STYLE="width: 34%; text-align: center; font-family: Times New Roman, Times, Serif">
&nbsp;
</TD>
<TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV> <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
 <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt"></P> </BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g140983image_001a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g140983image_001a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P ($# 2(  A$! Q$!_\0
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ES@2&(=E'7W/K5FL,1651I15HK1'1AJ#I)N;O*6K"BBBN<Z3_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
